Limen Prior Art: 18 Patent Families, No Patent Position
Concept study · Research only · No human testing · Not available · No development program exists
The bounded map is already populated. Eighteen patent families contain claim language adjacent to one or more Limen technical questions. That does not determine whether any claim covers Limen, whether a right is still in force, whether the claimed systems work, or whether any route should be selected.
What the result means
The review records 18 deduplicated families, 38 independently inspected independent claims, 35 source records, 19 logged searches, 12 bounded overlap hypotheses, and 10 technical search themes. Independent QA passed the exact package, and the Integrator reproduced the unchanged bytes after QA.
The result is a map of adjacent claim text. It is not an exhaustive prior-art search, a claim chart, a novelty or patentability opinion, an infringement analysis, a freedom-to-operate opinion, legal clearance, or evidence that a biological system performs as claimed.
Claims are not experiments. A patent can describe or claim an arrangement without establishing natural neural information, usable simultaneous duplex operation, chronic stability, safety, efficacy, or user advantage.
Where the bounded claim map is densest
| Cluster | What was found | What remains unproved |
|---|---|---|
| Combination leads | PAF-003, PAF-004, and PAF-017 recite different combinations of a control-recording path and sensory stimulation. | Direct-natural-ENG identity, same-participant and same-interface operation, usable simultaneity, artifact adequacy, sensory effect, chronic performance, and the complete frozen route. |
| Simultaneous operation | PAF-001 dependent claim 16 recites simultaneous operation of stimulation and monitoring apparatus. | Usable duplex, preserved biological information, natural ENG, artifact rejection, residual-contamination limits, route match, or long-term performance. |
| Artifact processing | PAF-009 and PAF-010 contain artifact-estimation or cancellation claim language. | Peripheral-prosthesis route identity, empirical rejection adequacy, preserved natural ENG, or simultaneous functional performance. |
| Removable-route themes | PAF-011, PAF-012, and PAF-015 map to surface-EMG training, EMG calibration, and external electrotactile feedback. | A complete optimized removable route, lower burden, comparator advantage, and broad vibrotactile-only coverage. |
| Interface and stability language | Cuff, penetrating, intrafascicular, regenerative, fixation, healing, fitting, and duration-labelled claim themes appear across several families. | Signal survival, tissue response, failure rates, revision, repair, explant, lifetime performance, safety, or readiness. |
The distinctions the report must not erase
- Direct natural peripheral-nerve ENG is not muscle EMG and is not an evoked CAP or CMAP.
- A stimulation command is not proof of delivered stimulation, and delivery is not proof of a useful sensory effect.
- Claim language for simultaneous operation is not evidence of usable duplex recording during stimulation.
- Artifact-estimation or filtering claim scope is not evidence that biological information survives with bounded contamination.
- A claim combining recorded control and stimulation components is not a demonstrated complete route.
- Duration-labelled stability language in a claim is not longitudinal biological or device evidence.
- An external or removable component is not automatically lower burden; non-wear, refit, doffing, shift, skin effects, and recalibration still require evidence.
What no inspected claim establishes
No inspected independent claim in this bounded corpus expressly combines every frozen invasive-route element with the frozen population, vision-occluded contact-and-release endpoint, and prospectively fixed adequate duration. That is a bounded corpus observation—not evidence that no such claim exists.
Nothing in the inspected patent claim evidence establishes or changes scientific route selection, comparator advantage, natural-ENG performance, usable duplex operation, chronic stability, safety, efficacy, feasibility, repairability, or readiness. The accepted Science result therefore remains unchanged: the invasive and optimized removable routes are both UNKNOWN, the bounded comparison remains OPEN_BOUNDED, and the Science disposition remains PROPOSED_HOLD.
Grant, ownership, and current force remain unresolved
Every registered family has an observed publication or grant event, but current-force determinations are zero. A publication or grant does not show that a claim remains in force, enforceable, validated, maintained, or owned today by the entity shown on a publication face.
Official U.S. file-wrapper and present-status access was restricted during the review. Some U.S. and PCT publication facsimiles were inspected through secondary delivery hosts; six families received an official EPO or national-journal supplement. These records strengthen identity and bibliographic traceability, not present legal status.
For PAF-001, the US6456866B1 publication face does not name Case Western Reserve University as assignee. No post-publication assignment event is established in the package, and present ownership remains unknown.
What this changes for Limen
The map changes one thing: it removes any excuse to treat the patent landscape as empty. Adjacent claim language exists across neural recording, sensory stimulation, combined prosthetic systems, interface structures, artifact processing, calibration, removable EMG, external feedback, and maintenance themes.
It does not identify a forbidden design, a safe design-around, a patentable concept, a licensable right, or an architecture to build. Limen still lacks the fixed implementation required for meaningful element-by-element legal analysis. Science still has not selected a route.
What happens before any patent position
- If separately authorized by the founder and Integrator under the governing gates, freeze a research-only proposed implementation specification for qualified counsel. Science and governance evidence inform that decision; they do not authorize development. Counsel cannot chart an unspecified concept.
- Reopen current official records. Check continuity, amendments, grants, oppositions, validations, fees, term, disclaimers, assignments, lapses, revivals, and present claim sets in each material jurisdiction.
- Prepare live-claim charts through qualified patent counsel. Compare the fixed implementation against claims actually in force, not family titles or abstracts.
- Broaden the prior-art search deliberately. Add classifications, citation descendants, assignee and inventor routes, non-patent literature, non-English records, and later-published applications without treating absence as proof.
- Keep legal and scientific evidence separate. Patent claim scope cannot close the open Science questions or authorize design work.
Verification and custody
Accepted package: 9 files, 111,356 bytes, registry 81f45ecd44003fc0d55725af0c360bc68b0f0eb31f8103b1565483a83157bd96. Fresh QA: NB-LIMEN-DEEP-03-LANE-C-R4-QA-01, P0/P1/P2/P3 = 0/0/0/0. Post-QA acceptance-evidence registry: cddb3aa36b6c283290d178b97b69c6ed58939d38364049374a60bbfc910a8a0e.
The patent package's frozen Science input is deep-review-02: 15 files, 188,248 bytes, registry c28e71ad7d0556c4bbbf9432eb7664f778dc4e16c343a70327c7df104f5397b2. The current Science cross-reference is the separately accepted deep-review-03: 16 files, 228,987 bytes, registry e0772c0caf7ae5631b82de5246f706d019cdce5b787d5973523cf82dbc141e4e, with Step 7 merge registry ed6c81ba0c1762e0acc106a40034f5d7aa28472ae3212a8fcb56664f62b12ca7. These snapshots remain separate, untracked, and unstaged.
Local source paths: docs/legal/limen/prior-art-01/README.md · docs/legal/limen/prior-art-01/claim-theme-matrix.tsv · docs/legal/limen/prior-art-01/overlap-and-gap-hypotheses.md · docs/review/evidence/limen-prior-art-01-r4-2026-08-30/ · docs/review/evidence/limen-step6-step7-inputs-2026-08-30/
A checksum proves identity, not scientific truth, legal force, ownership, clearance, or permission.